Health news
Bayer, long a household word in cardiovascular diseases and women’s health, is distinguishing itself in new blockbuster candidates and novel platforms while adding to its traditional strength.For instance, the global pharmaceutical giant is undergoing …
Merck’s KEYTRUDA ® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial.
When it comes to bioidentical hormone replacement therapy (BHRT), the Biote Method is the preferred choice among more than 4,800+ physicians.
TUESDAY, March 1, 2022 (HealthDay News) — Women who enter menopause early may be more likely to develop dementia later in life, new research indicates.
TUESDAY, March 1, 2022 (HealthDay News) — Women who enter menopause early may be more likely to develop dementia later in life, new research indicates.
DR ELLIE CANNON: Today’s reader wants to know whether it is possible to resume hormone replacement therapy as she is suffering many symptoms of the menopause.
“Male menopause” is a more well-known term for andropause, and that encompasses age-related changes in hormone levels among men.
U.S. FDA Approves Opdivo with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
From the use of anti-depressants to cryotherapy, researchers continue to explore potential ways to mitigate the side effects that are associated with breast cancer therapy.
Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.
![[Special Interview] Bayer, strong in CV, female health areas, is trailblazer in cell and gene fields, too](http://cdn.koreabiomed.com/news/thumbnail/202203/13240_13731_1232_v150.jpg "[Special Interview] Bayer, strong in CV, female health areas, is trailblazer in cell and gene fields, too")
